$350 Million is the total value of Opaleye Management Inc.'s 38 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 65.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXGN | Sell | AXOGEN INC | $62,597,000 | +12.3% | 1,715,000 | -12.9% | 17.90% | +0.3% |
| BPMC | Sell | BLUEPRINT MEDICINES | $55,020,000 | -0.7% | 600,000 | -18.4% | 15.73% | -11.4% |
| LOXO | Buy | LOXO ONCOLOGY | $20,697,000 | +39.5% | 179,400 | +1.8% | 5.92% | +24.5% |
| CDXS | CODEXIS INC | $18,706,000 | +31.7% | 1,700,600 | 0.0% | 5.35% | +17.6% | |
| FGEN | FIBROGEN INC | $16,632,000 | -2.5% | 360,000 | 0.0% | 4.76% | -13.0% | |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $14,071,000 | +55.3% | 1,590,000 | +27.2% | 4.02% | +38.6% |
| CORI | Buy | CORIUM INTERNATIONAL INC | $12,215,000 | +19.9% | 1,065,000 | +0.5% | 3.49% | +7.1% |
| AGIO | AGIOS PHARMACEUTICALS | $10,631,000 | +43.0% | 130,000 | 0.0% | 3.04% | +27.7% | |
| FENC | Buy | FENNEC PHARMACEUTICALS INC | $10,559,000 | +24.4% | 873,000 | +3.1% | 3.02% | +11.1% |
| SGMO | Sell | SANGAMO BIOSCIENCES INC | $10,165,000 | +6.9% | 535,000 | -7.8% | 2.91% | -4.6% |
| CBAY | CYMABAY THERAPEUTICS INC | $8,638,000 | +41.2% | 665,000 | 0.0% | 2.47% | +26.1% | |
| New | AMAG PHARMACEUTICALS INC | $8,463,000 | – | 420,000 | +100.0% | 2.42% | – | |
| New | MIRAGEN THERAPEUTICS INC | $7,430,000 | – | 1,060,000 | +100.0% | 2.12% | – | |
| DCPH | New | DECIPHERA PHARMACEUTICALS INC | $7,314,000 | – | 365,000 | +100.0% | 2.09% | – |
| New | OCULAR THERAPEUTIX INC | $7,232,000 | – | 1,111,000 | +100.0% | 2.07% | – | |
| XOMA | XOMA CORP DEL | $6,477,000 | -43.2% | 320,200 | 0.0% | 1.85% | -49.3% | |
| New | BIOFRONTERA AGsponsored ads | $6,462,000 | – | 391,200 | +100.0% | 1.85% | – | |
| ARDX | Buy | ARDELYX | $5,734,000 | -3.5% | 1,135,600 | +26.2% | 1.64% | -13.8% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $5,709,000 | -14.2% | 190,000 | -9.5% | 1.63% | -23.4% |
| AMRN | Buy | AMARIN CORP PLCsponsored adr | $5,252,000 | +52.3% | 1,745,000 | +102.9% | 1.50% | +36.1% |
| Sell | ABLYNX NVsponsored adr | $4,910,000 | -53.2% | 90,000 | -78.6% | 1.40% | -58.2% | |
| FOMX | Sell | FOAMIX PHARMACEUTICALS LTD | $4,873,000 | -15.5% | 950,000 | -1.0% | 1.39% | -24.6% |
| VKTX | Buy | VIKING THERAPEUTICS INC | $4,810,000 | +146.5% | 1,100,800 | +129.1% | 1.38% | +120.0% |
| RARE | Sell | ULTRAGENYX PHARMACEUTICALS INC | $4,079,000 | -2.3% | 80,000 | -11.1% | 1.17% | -12.8% |
| ACHN | Buy | ACHILLION PHARMACEUTICALS INC | $4,063,000 | +220.7% | 1,095,100 | +148.9% | 1.16% | +186.2% |
| DEPO | New | DEPOMED INC | $3,954,000 | – | 600,000 | +100.0% | 1.13% | – |
| PTCT | New | PTC THERAPEUTICS INC | $3,923,000 | – | 145,000 | +100.0% | 1.12% | – |
| TGTX | New | TG THERAPEUTICS INC | $3,893,000 | – | 274,200 | +100.0% | 1.11% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $3,166,000 | – | 222,500 | +100.0% | 0.90% | – |
| CMRX | CHIMERIX INC | $3,120,000 | +12.3% | 600,000 | 0.0% | 0.89% | +0.2% | |
| QTRX | Buy | QUANTERIX CORP | $2,556,000 | +83.2% | 150,000 | +130.8% | 0.73% | +63.5% |
| PLX | Buy | PROTALIX BIOTHERAPEUTICS INC | $1,760,000 | +45.9% | 3,260,000 | +78.6% | 0.50% | +30.3% |
| FBIO | New | FORTRESS BIOTECH INC | $1,433,000 | – | 315,000 | +100.0% | 0.41% | – |
| EPZM | New | EPIZYME INC | $1,242,000 | – | 70,000 | +100.0% | 0.36% | – |
| SYRS | SYROS PHARMACEUTICALS INC | $961,000 | +33.5% | 74,074 | 0.0% | 0.28% | +19.0% | |
| ZSAN | New | ZOSANO PHARMA CORP | $504,000 | – | 100,000 | +100.0% | 0.14% | – |
| QTNT | New | QUOTIENT LTD | $282,000 | – | 60,000 | +100.0% | 0.08% | – |
| BLRX | BIOLINERX LTDsponsored adr | $214,000 | -21.3% | 250,000 | 0.0% | 0.06% | -29.9% | |
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -31,000 | -100.0% | -0.19% | – |
| RYTM | Exit | RHYTHM PHARMACEUTICALS INC | $0 | – | -38,300 | -100.0% | -0.36% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -90,801 | -100.0% | -0.57% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -100,000 | -100.0% | -0.89% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -101,500 | -100.0% | -1.38% | – |
| ITEK | Exit | INOTEK PHARMACEUTICALS CORP | $0 | – | -1,802,000 | -100.0% | -1.51% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -80,000 | -100.0% | -1.53% | – |
| ARGX | Exit | ARGENXsponsored adr | $0 | – | -88,500 | -100.0% | -1.79% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -281,000 | -100.0% | -2.11% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -898,800 | -100.0% | -4.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.